Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
NCT04885907
Completed
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1 months. Participants will be randomized 1:1 to receive either a third dose of the mRNA-1273 vaccine or saline placebo at 3 months post initial vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2022
Locations: University Health Network, Toronto General Hospital, Toronto, Ontario +1 locations
Conditions: Vaccine Response Impaired, Immune Suppression, Covid19
Register for Updates
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
NCT03636906
Completed
The purpose of this study is to provide critical information on the safety, reactogenicity and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type 155-vectored RSV (ChAd155-RSV) vaccine in infants likely to be unexposed to RSV and will assess a single lower dose and a higher two dose regimen, before moving to future studies. This study will also assess if there is a risk of 'vaccine-induced enhanced RSV disease' after vaccination of these infants with the ChAd155... Read More
Gender:
ALL
Ages:
Between 6 months and 7 months
Trial Updated:
07/05/2022
Locations: GSK Investigational Site, Atlanta, Georgia +36 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccinating Children After Chemotherapy
NCT02447718
Completed
This multi-center open label clinical trial aims to identify predictors of low antibody titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6 months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and 13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months post-chemotherapy, followed by 23-valent pneumococcal poly... Read More
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
06/22/2022
Locations: IWK Health Centre, Halifax, Nova Scotia
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
NCT00940940
Completed
Varicella zoster virus is part of the herpesvirus group and causes chickenpox in exposed individuals. The majority of the population is seropositive for this virus. Reactivation of varicella zoster virus occurs in up to 30% of the general population over 60 years old. Solid organ transplant recipients receive lifelong immunosuppression drugs and are at great risk of reactivation of all herpesviruses including the varicella zoster virus regardless of age. The vaccine has been shown to be effecti... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/26/2022
Locations: University of Alberta Hospital, Edmonton, Alberta
Conditions: Kidney Transplant
Register for Updates
A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada
NCT03958799
Completed
The primary objectives of this study are: * To describe the safety profile of each of the investigational vaccine formulations for all participants * To describe the humoral and cell-mediated immune responses to all of the investigational vaccine formulations * To evaluate the dose response to vaccine components * To describe the magnitude, quality, and longevity of immune responses to each of the investigational vaccine formulations
Gender:
ALL
Ages:
Between 19 years and 21 years
Trial Updated:
04/21/2022
Locations: Investigational Site Number 1240006, Halifax, Not set +4 locations
Conditions: Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)
Register for Updates
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
NCT03698279
Completed
The objectives of this study were: * To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including adverse events of special interest throughout the study). * To describe the antibody response induced by each dosage of QIV-HD used in the study compared with unadjuvanted standard-dose quadrivalent influenza vaccine (QIV-SD) by hemagglutination inhibition (HAI) measu... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
03/24/2022
Locations: Investigational Site Number 8400004, San Diego, California +15 locations
Conditions: Influenza
Register for Updates
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
NCT03954743
Completed
The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan. This study used a purposely selected lot for PCV-free liquid HRV vaccine that is in the upper range of the usual release potencies. The PCV-free liquid HRV vaccine lots used were stored frozen in order to keep the titer stable until administration during the study. As the liquid formulation of G... Read More
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
02/25/2022
Locations: GSK Investigational Site, Birmingham, Alabama +36 locations
Conditions: Infections, Rotavirus
Register for Updates
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
NCT02737475
Completed
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/25/2021
Locations: University Of Colorado, Aurora, Colorado +21 locations
Conditions: Advanced Cancer
Register for Updates
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
NCT02787044
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Birmingham VAMC, Birmingham, Alabama +189 locations
Conditions: Heart Failure, Myocardial Infarction
Register for Updates
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
NCT02927873
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of the respiratory syncytial virus (RSV) candidate vaccine when first administered via intramuscular (IM) injection according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23 months.
Gender:
ALL
Ages:
Between 12 months and 23 months
Trial Updated:
09/28/2021
Locations: GSK Investigational Site, Anaheim, California +23 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
COVID-19 Vaccine For Indirect Protection
NCT04818736
Withdrawn
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in non-vaccinated Hutterite members.
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2021
Locations: McMaster University, Hamilton, Ontario
Conditions: Vaccine Preventable Disease
Register for Updates
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
NCT02075515
Completed
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Mesa, Arizona +7 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates